Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE Eligible patients were anti-TNF naïve adults with moderately to severely active UC. 29372480 2018
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE To assess comparative efficacy and safety of different therapies as first-line (biologic-naïve) and second-line (prior exposure to anti-tumour necrosis factor(TNF)-α) agents for moderate-severe UC, through a systematic review and network meta-analysis, and appraise quality of evidence (QoE) using grading of recommendations, assessment, development and evaluation (GRADE) approach. 29205406 2018
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE Adalimumab is a recombinant monoclonal antibody to tumor necrosis factor alpha (TNFα) used in the treatment of inflammatory and autoimmune conditions, including ulcerative colitis (UC). 30648028 2018
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 GeneticVariation disease BEFREE Combination therapy was not superior in any of the registration trials for Crohn's disease and ulcerative colitis for TNF antagonists, vedolizumab, or ustekinumab. 29462391 2018
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE The cumulative incidence of anti-TNF exposure varied from 20.9% to 31.4% for CD and from 8.0% to 13.5% for UC. 30205699 2018
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE The risk of death was statistically significantly lower in patients treated with anti-TNF therapy for CD (21.4 vs. 30.1 per 1,000 person-years, OR 0.78, 0.65-0.93) but not for UC (23.0 vs. 30.9 per 1,000 person-years, OR 0.87, 0.63-1.22). 29336432 2018
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 GeneticVariation disease BEFREE Based on the results of the pivotal clinical GEMINI trials, vedolizumab was approved for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) refractory or intolerant to either conventional therapy or TNFα inhibitors. 29930467 2018
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE CD was more commonly treated with anti-TNF than UC (40% vs. 10%, p<0.001). 30009157 2018
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE Compared with the model group, the general relative indices results showed L. plantarum ZDY2013 and B. bifidum WBIN03 have a significant effect on DSS-induced UC in mice, by downregulating the pro-inflammatory cytokines (e.g., TNF-α) and upregulating antioxidant factors (e.g., SOD1, SOD2, GPX2) at the transcriptional level. 29401402 2018
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE Randomized controlled trials (RCTs) have demonstrated that therapies targeting tumor necrosis factor (TNF) and α₄β₇ integrin are effective when given as monotherapy in inducing and/or maintaining remission in patients with ulcerative colitis (UC) or Crohn's disease (CD), but data from RCTs are less clear on whether concomitant immunomodulator (IM) therapy confers additional benefit. 29505910 2018
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE Ninety five adults with steroid-dependent active UC and insufficient response/intolerance to IS and/or TNF inhibitors received 5-8 aphereses in a single induction series of ≤10 weeks. 29513111 2018
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE COX-2-PGE<sub>2</sub> Signaling Impairs Intestinal Epithelial Regeneration and Associates with TNF Inhibitor Responsiveness in Ulcerative Colitis. 30190207 2018
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 AlteredExpression disease BEFREE In conclusion, CX-10 treatment attenuated DSS-induced UC in mice through inhibiting the activation of NF-κB and MAPK pathways and reducing TNF-α and IL-6 levels, suggesting that CX-10 is a potential therapeutic drug for UC. 29475099 2018
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 AlteredExpression disease BEFREE A cohort of 103 IBD patients (80 CD, 23 UC) were genotyped and serum level of both anti-TNFs (infliximab or adalimumab) and ADA against them were measured. 29333082 2018
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 AlteredExpression disease BEFREE Results show that the UC group had higher expression levels of TNF-α, IL-6, IFN-γ, MPO, MDA, NO, STAT3 and JAK and lower expression levels of IL-10, SOD, miR-495 and Claudin-1, compared to the normal group. 29129493 2018
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE Here, we show that levels of peripheral blood cytokines IL-9, IL-8, IL-10, IL-6, IL-1β, IL-12, and tumor necrosis factor (TNF) were higher in patients with UC than normal control, and serum and local IL-9 levels were positively correlated with the disease activity grade. 30369485 2018
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE Systematic Review With Meta-Analysis: Anti-TNF Therapy in Refractory Pouchitis and Crohn's Disease-Like Complications of the Pouch After Ileal Pouch-Anal Anastomosis Following Colectomy for Ulcerative Colitis. 29361101 2018
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 AlteredExpression disease BEFREE Also HASG was found to reduce the levels of TNF-α and IL-6, thereby suppressing their inflammatory response in UC. 29530609 2018
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 AlteredExpression disease BEFREE TNFα was upregulated in intestinal biopsies from active Crohn`s disease [CD] vs controls [36.2 vs 12.1, p < 0.001], but not ulcerative colitis [UC: 17.9]. 29182760 2018
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE Orally targeted galactosylated chitosan poly(lactic-co-glycolic acid) nanoparticles loaded with TNF-ɑ siRNA provide a novel strategy for the experimental treatment of ulcerative colitis. 30315858 2018
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 AlteredExpression disease BEFREE Circulating monocytes from active ulcerative colitis (UC) patients produced high levels of tumor necrosis factor-alpha(TNFα) and interleukin(IL)-6 after Toll-like receptors (TLR) stimulation. 29529212 2018
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 GeneticVariation disease BEFREE As combination therapy is an emerging strategy for UC treatment, we attempt to treat established UC based on the combination of TNFα siRNA (siTNF) and IL-22. 30107214 2018
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 AlteredExpression disease BEFREE In addition, bioptic samples from UC patients incubated with LGG conditioned media (CM) showed reduced expression of TNFα and IL-17 compared with the corresponding expression in controls (<i>P</i> < 0.05). 30416313 2018
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 AlteredExpression disease BEFREE Both CD and UC samples exhibited gene and protein expression of HLA-G; and the HLA-G5 expression is differentially correlated with TNF and IL-10 levels depending on the type of the underlying inflammatory bowel disorder. 29588183 2018
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 AlteredExpression disease BEFREE In ulcerative colitis (UC) patients, cytapheresis depletes elevated and activated leucocytes, which are known to release inflammatory cytokines including tumor necrosis factor (TNF)-α. 28581039 2018